These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34332931)

  • 1. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
    Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R
    Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.
    Wu TH; Lee LJ; Yuan CT; Chen TW; Yang JC
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):230-236. PubMed ID: 29709339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of pleural biopsy for the diagnosis of histologic subtype of malignant pleural mesothelioma: Necropsy-based study of 134 cases.
    Barbieri PG; Consonni D; Schneider M
    Tumori; 2022 Feb; 108(1):26-32. PubMed ID: 33719756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma.
    Ollila H; Paajanen J; Wolff H; Ilonen I; Sutinen E; Välimäki K; Östman A; Anttila S; Kettunen E; Räsänen J; Kallioniemi O; Myllärniemi M; Mäyränpää MI; Pellinen T
    J Pathol Clin Res; 2021 Sep; 7(5):482-494. PubMed ID: 33955203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
    Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
    BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma?
    Kim S; Bull DA; Garland L; Khalpey Z; Stea B; Yi S; Hsu CC
    Ann Thorac Surg; 2019 Jan; 107(1):194-201. PubMed ID: 30278171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disparities in Compliance With National Guidelines for the Treatment of Malignant Pleural Mesothelioma.
    Espinoza-Mercado F; Borgella JD; Berz D; Alban RF; Sarkissian A; Imai HTA; Soukiasian HJ
    Ann Thorac Surg; 2019 Sep; 108(3):889-896. PubMed ID: 31004585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
    Rena O; Boldorini R; Papalia E; Mezzapelle R; Baietto G; Roncon A; Casadio C
    Ann Thorac Surg; 2015 Apr; 99(4):1177-83. PubMed ID: 25669666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.
    Suzuki H; Asami K; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Okishio K; Kawaguchi T; Atagi S; Kawase I
    Lung; 2014 Feb; 192(1):191-5. PubMed ID: 24141556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.
    Raphael J; Massard C; Gong IY; Farace F; Margery J; Billiot F; Hollebecque A; Besse B; Soria JC; Planchard D
    Cancer Biomark; 2015; 15(2):151-6. PubMed ID: 25519011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting survival in malignant pleural mesothelioma using routine clinical and laboratory characteristics.
    Gunatilake S; Lodge D; Neville D; Jones T; Fogg C; Bassett P; Begum S; Kerley S; Marshall L; Glaysher S; Elliott S; Stores R; Bishop L; Chauhan A
    BMJ Open Respir Res; 2021 Jan; 8(1):. PubMed ID: 33414260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.
    Thies S; Friess M; Frischknecht L; Korol D; Felley-Bosco E; Stahel R; Vrugt B; Weder W; Opitz I; Soltermann A
    PLoS One; 2015; 10(9):e0139312. PubMed ID: 26421614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
    de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
    Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
    Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
    Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis.
    Brims FJ; Meniawy TM; Duffus I; de Fonseka D; Segal A; Creaney J; Maskell N; Lake RA; de Klerk N; Nowak AK
    J Thorac Oncol; 2016 Apr; 11(4):573-82. PubMed ID: 26776867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results.
    Lococo F; Rena O; Torricelli F; Filice A; Rapicetta C; Boldorini R; Paci M; Versari A
    Interact Cardiovasc Thorac Surg; 2020 Apr; 30(4):593-596. PubMed ID: 32003806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy.
    Frick AE; Nackaerts K; Moons J; Lievens Y; Verbeken E; Lambrecht M; Coolen J; Dooms C; Vansteenkiste J; De Leyn P; Nafteux P
    Eur J Cardiothorac Surg; 2019 May; 55(5):934-941. PubMed ID: 30535191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction modeling using routine clinical parameters to stratify survival in malignant pleural mesothelioma patients complicated with malignant pleural effusion.
    Zhang S; Zhang Y; Feng W; Shi Z; Shi H; Zhang Y
    Thorac Cancer; 2021 Dec; 12(24):3304-3309. PubMed ID: 34704370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early-stage Clinical Characterization of Malignant Pleural Mesothelioma.
    Negi Y; Kuribayashi K; Funaguchi N; Doi H; Mikami K; Minami T; Takuwa T; Yokoi T; Hasegawa S; Kijima T
    In Vivo; 2018; 32(5):1169-1174. PubMed ID: 30150440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.